News on science and technology in Texas

Provided by AGP

Got News to Share?

Texas Technology Digest: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Texas Technology Digest.

Press releases published on April 17, 2026

Sparks Police Department Launches DeskOfficer AI to Support Non-Emergency Calls in 911 Center
Mente Group Welcomes the Return of Kyle Bonda as Senior Managing Director
Crypto News: AlphaPepe Announces $870k Raised Amid Dogecoin Price Prediction Targeting $0.47 Following X Money Beta Launch
Fyresite Reaches New Heights With Shopify Premier Partner Promotion
Rocket Doctor Amends 45 Degree Agreement
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting
Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BGIN BLOCKCHAIN LIMITED Schedules the Fiscal Year 2025 Earnings and Conference Call on April 24, 2026
TTEC Schedules First Quarter 2026 Earnings Release and Webcast of Investor Conference Call
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting
4DMT Announces New Employment Inducement Grants
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SEALSQ Announces Agenda of its 2026 Annual General Meeting of Shareholders
ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual Meeting
Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026
Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types

Share us

on your social networks:

Sign up for:

Texas Technology Digest

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.